Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.48 HKD | -1.82% | +7.11% | -10.74% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.81 for the current year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.74% | 9.99B | B | ||
+34.87% | 664B | C+ | ||
+29.25% | 567B | B | ||
-7.13% | 354B | C+ | ||
+19.44% | 330B | B- | ||
+4.53% | 286B | C+ | ||
+13.40% | 234B | B+ | ||
+5.29% | 199B | B- | ||
-9.94% | 196B | A+ | ||
-4.87% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1093 Stock
- Ratings CSPC Pharmaceutical Group Ltd.